论文部分内容阅读
目的:探讨TIP30、EGFR在HER-2阳性乳腺癌诊疗中的价值。方法:选取行手术切除治疗的64例HER-2阳性乳腺癌患者为研究对象,采用免疫组化法分析患者乳腺癌组织TIP30、EGFR表达情况,并对数据进行分析。结果:共有37例HER-2阳性乳腺癌患者TIP30阳性表达,阳性率为57.81%,且TIP30阳性表达与患者的年龄、病理类型、转移部位数、TNM分型均无明显相关性(P>0.05),仅与ECOG PS评分显著相关(P=0.000);共有17例HER-2阳性乳腺癌患者EGFR阳性表达,阳性率为26.56%,且EGFR阳性表达与患者的年龄、病理类型、转移部位数及ECOG PS评分均无明显相关性(P>0.05),仅与TNM分型显著相关(P=0.014)。HER-2阳性乳腺癌患者无进展生存期(PFS)与TIP30、ECOG PS评分、TNM分型显著相关(P<0.05),HER-2阳性乳腺癌患者预后独立危险因素包括TIP30阳性、ECOG PS评分为2分、TNM分型为Ⅲ期(P<0.05)。TIP30与EGFR在HER-2阳性乳腺癌患者中的表达呈明显负相关性(r=-0.341,P=0.014)。结论:TIP30阳性是HER-2阳性乳腺癌患者PFS的一个独立预测因素,且TIP30与EGFR在HER-2阳性乳腺癌患者中的表达呈明显负相关性。
Objective: To investigate the value of TIP30 and EGFR in the diagnosis and treatment of HER-2 positive breast cancer. Methods: Sixty-four patients with HER-2-positive breast cancer who underwent surgical resection were enrolled in this study. The expression of TIP30 and EGFR in breast cancer tissues was analyzed by immunohistochemistry and the data were analyzed. Results: TIP30 expression was positive in 37 cases of HER-2 positive breast cancer, the positive rate was 57.81%. There was no significant correlation between the expression of TIP30 and the age, pathological type, metastasis location and TNM classification (P> 0.05 ), But only significantly correlated with ECOG PS score (P = 0.000). A total of 17 cases of HER-2 positive breast cancer patients had positive EGFR expression, with a positive rate of 26.56%. The positive expression of EGFR correlated with age, pathological type, And ECOG PS scores were not significantly correlated (P> 0.05), only with TNM type was significantly correlated (P = 0.014). The progression-free survival (PFS) of patients with HER-2 positive breast cancer was significantly correlated with TIP30, ECOG PS score and TNM classification (P <0.05). The independent prognostic risk factors of HER-2 positive breast cancer patients included TIP30 positive and ECOG PS 2 points, TNM type Ⅲ (P <0.05). The expression of TIP30 and EGFR in HER-2 positive breast cancer patients was negatively correlated (r = -0.341, P = 0.014). CONCLUSION: TIP30-positive is an independent predictor of PFS in patients with HER-2-positive breast cancer, and the expression of TIP30 and EGFR in HER-2-positive breast cancer patients is negatively correlated.